高钾血症治疗的关键临床试验、荟萃分析与现行指南
本综述总结了心肾患者慢性高钾血症治疗的当前证据。高钾血症在晚期CKD患者中最常见,危及生命且影响预后;RAAS抑制剂本身升高血钾,常导致其停用或减量。现有降钾策略疗效有限且耐受性差,新型钾结合剂可能改变治疗格局。
要点
- 高钾血症是晚期CKD最常见电解质紊乱,增加致命性心律失常风险。
- RAAS抑制剂心肾保护但升高血钾,常因高钾而停用或减量。
- 现有降钾策略疗效有限且耐受性差,新型钾结合剂带来新选择。
核心结论
- 现有预防和治疗慢性高钾血症的策略仍不令人满意,即使稳定肾科治疗患者和随机临床试验理想设置下高钾血症患病率仍较高。
- 新型钾结合剂可能改变心肾患者慢性高钾血症的治疗格局。
研究设计与样本
- 本文为综述,总结心肾患者慢性高钾血症治疗的当前证据,涵盖关键临床试验、荟萃分析和现行指南。
主要发现
- 高钾血症是晚期CKD患者最常见的电解质紊乱,因致命性心律失常风险而可能危及生命,并严重影响CKD患者生活质量和预后。
- RAAS抑制剂治疗本身升高血钾,尤其当心力衰竭和糖尿病共存时;高钾血症的发生或复发常与未启动、下调或停用RAAS抑制剂相关,并且是终末期肾病开始肾脏替代治疗的指征。
- 饮食限钾、使用碳酸氢钠或利尿剂、停用或下调RAAS抑制剂、或使用旧钾结合剂(聚苯乙烯磺酸钠和聚苯乙烯磺酸钙)疗效有限且耐受性差,不适合长期控制血钾。
临床怎么用
- 临床需重视RAAS抑制剂相关高钾血症,避免因高钾而不恰当地停用或下调RAAS抑制剂。
- 现有降钾策略不适合长期控制血钾,可关注新型钾结合剂的应用前景。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hyperkalemia (HK) is the most common electrolyte disturbance observed in patients with advanced stages of chronic kidney disease (CKD), is a potentially life-threatening clinical condition due to an increased risk of fatal arrhythmias, and strongly impacts the quality of life and prognosis of CKD patients. Moreover, while renin-angiotensin-aldosterone system inhibitors (RAASIs) represent the most cardio-nephro-protective drugs used in clinical practice, the treatment with these drugs per se increases serum potassium (sK) values, particularly when heart failure and diabetes mellitus coexist. In fact, the onset or recurrence of HK is frequently associated with not starting, down-titrating or withdrawing RAASIs, and is an indication to begin renal replacement treatment in end-stage renal disease. Current strategies aimed at preventing and treating chronic HK are still unsatisfactory, as evidenced by the relatively high prevalence of HK also in patients under stable nephrology care, and even in the ideal setting of randomized clinical trials. Indeed, dietary potassium restriction, the use of sodium bicarbonate or diuretics, the withdrawal or down-titration of RAASIs, or the administration of old potassium binders, namely sodium polystyrene sulphonate and calcium polystyrene sulphonate, have limited efficacy and are poorly tolerated; therefore, these strategies are not suitable for long-term control of sK. As such, there is an important unmet need for novel therapeutic options for the chronic management of patients at risk for HK. The development of new potassium binders may change the treatment landscape in the near future. This review summarizes the current evidence on the treatment of chronic HK in cardio-renal patients.
引用
- Bianchi S, Regolisti G. Pivotal clinical trials, meta-analyses and current guidelines in the treatment of hyperkalemia. Nephrol Dial Transplant. 2019. PMID: 31800075. doi:10.1093/ndt/gfz213
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。